[F-18]SDM-8

N/A

Report date: 2025/11/20 17:56:59

NME

Base Information

Drug Name[F-18]SDM-8

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSynaptic vesicle glycoprotein 2A modulatorsRadionuclide imaging enhancers

TargetsSynaptic vesicle glycoprotein 2A

Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe Brigham and Women's Hospital

China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's Hospital

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A